Nancy Braverman

Title: Nancy Braverman: Innovator in Gene Therapy

Introduction

Nancy Braverman is a prominent inventor based in Montreal, Canada. She has made significant contributions to the field of gene therapy, particularly in the treatment of peroxisomal disorders. Her innovative work has the potential to impact many lives by addressing complex genetic conditions.

Latest Patents

Nancy Braverman holds one patent related to gene therapy for treating peroxisomal biogenesis disorders (PBDs). This patent involves methods and compositions that utilize recombinant adeno-associated viruses (rAAV) to deliver a nucleic acid encoding human PEX1 to host cells. The rAAVs are designed with an AAV capsid and include a vector genome that comprises an AAV 5' inverted terminal repeat (ITR) sequence, a promoter, a coding sequence for human PEX1, and an AAV 3' ITR.

Career Highlights

Throughout her career, Nancy has worked at prestigious institutions such as the University of Pennsylvania and the University of Southern California. Her research has focused on advancing the understanding and treatment of genetic disorders, showcasing her dedication to improving patient outcomes.

Collaborations

Nancy Braverman has collaborated with notable colleagues, including Catherine Argyriou and Joseph Hacia. These partnerships have contributed to her research and the development of innovative therapeutic approaches.

Conclusion

Nancy Braverman is a trailblazer in the field of gene therapy, with her work on peroxisomal disorders paving the way for future advancements. Her contributions to science and medicine highlight the importance of innovation in addressing complex health challenges.